CN107625728A - 注射用缓释制剂 - Google Patents

注射用缓释制剂 Download PDF

Info

Publication number
CN107625728A
CN107625728A CN201710826877.XA CN201710826877A CN107625728A CN 107625728 A CN107625728 A CN 107625728A CN 201710826877 A CN201710826877 A CN 201710826877A CN 107625728 A CN107625728 A CN 107625728A
Authority
CN
China
Prior art keywords
solution
formulation
active ingredient
injection
crystals
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201710826877.XA
Other languages
English (en)
Chinese (zh)
Inventor
中川隆
小关宣雅
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma Co Ltd
Original Assignee
Sumitomo Dainippon Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Dainippon Pharma Co Ltd filed Critical Sumitomo Dainippon Pharma Co Ltd
Publication of CN107625728A publication Critical patent/CN107625728A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201710826877.XA 2010-10-18 2011-10-18 注射用缓释制剂 Pending CN107625728A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39406910P 2010-10-18 2010-10-18
US61/394069 2010-10-18
CN201180060225.0A CN103249416B (zh) 2010-10-18 2011-10-18 注射用缓释制剂

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201180060225.0A Division CN103249416B (zh) 2010-10-18 2011-10-18 注射用缓释制剂

Publications (1)

Publication Number Publication Date
CN107625728A true CN107625728A (zh) 2018-01-26

Family

ID=45933169

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201710826877.XA Pending CN107625728A (zh) 2010-10-18 2011-10-18 注射用缓释制剂
CN201180060225.0A Expired - Fee Related CN103249416B (zh) 2010-10-18 2011-10-18 注射用缓释制剂
CN201710826880.1A Pending CN107595771A (zh) 2010-10-18 2011-10-18 注射用缓释制剂

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201180060225.0A Expired - Fee Related CN103249416B (zh) 2010-10-18 2011-10-18 注射用缓释制剂
CN201710826880.1A Pending CN107595771A (zh) 2010-10-18 2011-10-18 注射用缓释制剂

Country Status (7)

Country Link
US (3) US9469630B2 (https=)
EP (1) EP2629775A4 (https=)
JP (4) JP5893616B2 (https=)
KR (1) KR101936968B1 (https=)
CN (3) CN107625728A (https=)
CA (1) CA2814840C (https=)
WO (1) WO2012053654A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR090775A1 (es) * 2012-04-23 2014-12-03 Otsuka Pharma Co Ltd Preparado inyectable
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
WO2014084921A1 (en) * 2012-11-27 2014-06-05 Rose Stuart Pharmaceutical manufacturing method and compositions
WO2014152562A1 (en) * 2013-03-15 2014-09-25 Epizyme, Inc. Injectable formulations for treating cancer
TW201609145A (zh) * 2013-12-25 2016-03-16 參天製藥股份有限公司 注射劑及形成緩釋（ｄｅｐｏｔ）之方法
WO2016044649A1 (en) * 2014-09-17 2016-03-24 Epizyme, Inc. Injectable formulations for treating cancer
KR101792414B1 (ko) * 2016-05-19 2017-11-01 삼성전기주식회사 박막 커패시터 및 그 제조방법
CN105963253A (zh) * 2016-06-19 2016-09-28 朱武欣 一种罗替戈汀长效水性混悬型注射剂
WO2018015915A1 (en) 2016-07-22 2018-01-25 Cadila Healthcare Limited A parenteral controlled release composition of an atypical antipsychotic agent
JPWO2018043613A1 (ja) * 2016-08-31 2019-06-24 大日本住友製薬株式会社 水性懸濁型製剤
US10252229B2 (en) * 2017-06-30 2019-04-09 Snowie LLC System comprising a pump attached to a tank casing for mixing a fluid
JPWO2019167978A1 (ja) 2018-02-28 2021-02-04 大日本住友製薬株式会社 溶出が制御された水性懸濁型医薬製剤
CN111989102A (zh) * 2018-02-28 2020-11-24 大日本住友制药株式会社 水性混悬液型药物制剂
JP7214103B2 (ja) * 2019-01-18 2023-01-30 株式会社大一商会 遊技機
JP7214100B2 (ja) * 2019-01-18 2023-01-30 株式会社大一商会 遊技機
JP7214102B2 (ja) * 2019-01-18 2023-01-30 株式会社大一商会 遊技機
JPWO2020179925A1 (https=) * 2019-03-07 2020-09-10
CN110478131B (zh) * 2019-08-05 2022-01-11 思必康（厦门）新材料有限公司 一种pH响应变色的纱布及其制备方法和该纱布的应用
US11041740B1 (en) 2019-12-20 2021-06-22 EmpNia Inc. Method and apparatus for real time respiratory gating signal generation and detection of body deformation using embedded fiber Bragg gratings
EP4126882A1 (en) * 2020-03-27 2023-02-08 Boston Scientific Scimed Inc. Methods for crystallization of drugs
WO2022034489A1 (en) * 2020-08-11 2022-02-17 Auxilla Pharmaceuticals And Research Llp A non-aqueous suspension of anticancer agent
CA3210098A1 (en) 2021-02-24 2022-09-01 Oakwood Laboratories, Llc Microsphere formulations comprising lurasidone and methods for making and using the same
CN116848108A (zh) 2021-03-31 2023-10-03 四川科伦药物研究院有限公司 一种鲁拉西酮可注射混悬液及其制备方法
CN120078778A (zh) * 2024-09-25 2025-06-03 山东百诺医药股份有限公司 一种伏硫西汀酯药物组合物及其制备方法和用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101198331A (zh) * 2005-06-13 2008-06-11 大日本住友制药株式会社 增溶化制剂

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2800953B2 (ja) * 1990-07-06 1998-09-21 住友製薬株式会社 新規なイミド誘導体
TW491847B (en) * 1996-05-07 2002-06-21 Pfizer Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
TW487572B (en) 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
US6617321B2 (en) 1997-09-30 2003-09-09 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
US6169084B1 (en) 1997-09-30 2001-01-02 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
FI105074B (fi) 1997-12-31 2000-06-15 Leiras Oy Farmaseuttisen formulaation valmistusmenetelmä
HK1041199B (en) 1998-09-30 2005-03-18 Eli Lilly & Company 2-Methyl-thiophenone-benzodiazine formula
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US20040022862A1 (en) 2000-12-22 2004-02-05 Kipp James E. Method for preparing small particles
WO2002078673A1 (fr) 2001-03-29 2002-10-10 Takeda Chemical Industries, Ltd. Procede de production d'un medicament sous forme de granules fins
JP4175800B2 (ja) 2001-11-27 2008-11-05 住友化学株式会社 イミド誘導体の製造方法
DE10218110A1 (de) 2002-04-23 2003-11-20 Jenapharm Gmbh Verfahren zum Herstellen von Kristallen von Arzneimittelhilfsstoffen, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
GB0216416D0 (en) * 2002-07-15 2002-08-21 Novartis Ag Organic compounds
KR101085806B1 (ko) 2003-07-29 2011-11-22 다이닛본 스미토모 세이야꾸 가부시끼가이샤 이미드 화합물의 제조 방법
US20050032811A1 (en) * 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
TWI371274B (en) 2003-10-23 2012-09-01 Bristol Myers Squibb Co Process for making sterile aripiprazole of desired mean particle size
UA82561C2 (uk) 2003-10-23 2008-04-25 Оцука Фармасьютикалз Ко., Лтд. Стерильна ін'єкційна композиція арипіпразолу з контрольованим вивільненням, спосіб її виготовлення та спосіб лікування шизофренії
CN101106972A (zh) 2004-11-16 2008-01-16 伊兰制药国际有限公司 注射用纳米微粒奥氮平制剂
SI1838716T1 (sl) 2005-01-05 2011-10-28 Lilly Co Eli Olanzapin pamoat dihidrat
RU2407529C2 (ru) 2005-04-13 2010-12-27 Пфайзер Продактс Инк. Инъецируемые препаративные формы депо и способы обеспечения замедленного высвобождения композиций, состоящих из наночастиц
DK1884242T3 (da) * 2005-05-26 2013-05-06 Dainippon Sumitomo Pharma Co Farmaceutisk sammensætning omfattende lurasidon
CA2622758A1 (en) 2005-09-15 2007-03-29 Elan Pharma International, Limited Nanoparticulate aripiprazole formulations
WO2007106768A2 (en) 2006-03-14 2007-09-20 Merck & Co., Inc. Processes and apparatuses for the production of crystalline organic microparticle compositions by micro-milling and crystallization on micro-seed and their use
BRPI0820745A2 (pt) 2007-12-13 2015-06-16 Novartis Ag Compostos orgânicos

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101198331A (zh) * 2005-06-13 2008-06-11 大日本住友制药株式会社 增溶化制剂

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
塔苏等: "《纳米粒药物输送系统》", 30 September 2010, 北京大学医学出版社 *
易红等: "几种注射用表面活性剂的质量标准及安全性概述", 《中国实验方剂学杂志》 *

Also Published As

Publication number Publication date
US20190010149A1 (en) 2019-01-10
JP6173502B2 (ja) 2017-08-02
KR101936968B1 (ko) 2019-01-09
CN103249416B (zh) 2019-06-04
JP5893616B2 (ja) 2016-03-23
EP2629775A1 (en) 2013-08-28
JP6410889B2 (ja) 2018-10-24
WO2012053654A1 (en) 2012-04-26
JP2017206543A (ja) 2017-11-24
JP2013543481A (ja) 2013-12-05
JP2016128503A (ja) 2016-07-14
CN103249416A (zh) 2013-08-14
CN107595771A (zh) 2018-01-19
EP2629775A4 (en) 2014-06-11
US20120091022A1 (en) 2012-04-19
CA2814840A1 (en) 2012-04-26
JP2019006822A (ja) 2019-01-17
US9469630B2 (en) 2016-10-18
US20160158228A1 (en) 2016-06-09
CA2814840C (en) 2018-08-28
KR20130139978A (ko) 2013-12-23

Similar Documents

Publication Publication Date Title
CN107625728A (zh) 注射用缓释制剂
US9545457B2 (en) Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
AU2010325632B2 (en) Process for preparing pharmaceutical ophthalmic compositions
JP2007532619A (ja) 懸濁したガラス粒子を含有する液体
JP2013512894A5 (https=)
JP2013543481A5 (https=)
KR101843613B1 (ko) 약제학적 페메트렉시드 액제
MD3769753T2 (ro) Procedeu de preparare a suspensiilor de nanocristale de propionat de fluticazonă Forma A apoase oftalmice sterile
NO880403L (no) Parenterale suspensjoner.
JP2025024083A (ja) 滅菌処理したヘテロシクリデンアセトアミド誘導体含有懸濁液
CN107233583A (zh) 一种具有超长持续时间的超声造影剂及其制备方法
RU2363447C2 (ru) Жидкости, содержащие суспендированные стекловидные частицы
TWI584823B (zh) 具有延長的保存期限的阿立哌唑可注射懸浮液製劑
WO2011016435A1 (ja) ポリ乳酸粒子含有凍結乾燥組成物の製造方法
Nail et al. Coarse suspensions: design and manufacturing

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180126

WD01 Invention patent application deemed withdrawn after publication